Home › Compare › KRBP vs BTI

KRBP vs BTI: Dividend Comparison 2026

KRBP yields 2469.14% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KRBP wins by $71690433869.06M in total portfolio value
10 years
KRBP
KRBP
● Live price
2469.14%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$71690433869.09M
Annual income
$66,400,343,104,095,020.00
Full KRBP calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — KRBP vs BTI

📍 KRBP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKRBPBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KRBP + BTI cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
KRBP pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KRBP
Annual income on $10K today (after 15% tax)
$209,876.54/yr
After 10yr DRIP, annual income (after tax)
$56,440,291,638,480,770.00/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, KRBP beats the other by $56,440,291,638,478,400.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KRBP + BTI for your $10,000?

KRBP: 50%BTI: 50%
100% BTI50/50100% KRBP
Portfolio after 10yr
$35845216934.57M
Annual income
$33,200,171,552,048,904.00/yr
Blended yield
92.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

KRBP
No analyst data
Altman Z
-36.0
Piotroski
2/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KRBP buys
0
BTI buys
0
No recent congressional trades found for KRBP or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKRBPBTI
Forward yield2469.14% ✓5.38%
Annual dividend / share$2.00$3.15 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3% ✓
Portfolio after 10y$71690433869.09M ✓$37.7K
Annual income after 10y$66,400,343,104,095,020.00 ✓$2,786.64
Total dividends collected$71320494496.27M ✓$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: KRBP vs BTI ($10,000, DRIP)

YearKRBP PortfolioKRBP Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$257,614$246,913.58$11,299$598.92+$246.3K → KRBP
2$6,220,347$5,944,700.13$12,794$703.91+$6.21M → KRBP
3$140,806,183$134,150,411.83$14,518$829.07+$140.79M → KRBP
4$2,988,682,073$2,838,019,457.81$16,513$978.64+$2988.67M → KRBP
5$59,495,451,401$56,297,561,582.68$18,827$1,157.84+$59495.43M → KRBP
6$1,111,053,579,695$1,047,393,446,695.76$21,518$1,373.12+$1111053.56M → KRBP
7$19,468,874,566,651$18,280,047,236,377.10$24,657$1,632.46+$19468874.54M → KRBP
8$320,195,562,728,668$299,363,866,942,351.70$28,329$1,945.74+$320195562.70M → KRBP
9$4,944,010,060,747,097$4,601,400,808,627,422.00$32,637$2,325.33+$4944010060.71M → KRBP
10$71,690,433,869,094,420$66,400,343,104,095,020.00$37,708$2,786.64+$71690433869.06M → KRBP

KRBP vs BTI: Complete Analysis 2026

KRBP — Stock

Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Full KRBP Calculator →

BTI — Consumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this KRBP vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KRBP vs SCHDKRBP vs JEPIKRBP vs OKRBP vs KOKRBP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.